Clinical Trials · global
Breast Cancer ADC Meets Phase 3 Endpoint but Shows Limited Benefit: BioNTech Reports Increased Lung Toxicity
Although trastuzumab pamirtecan delayed disease progression, the improvement was modest, and serious and fatal pulmonary adverse events occurred in the trial. The two developers are reassessing the benefits and risks to determine their next steps.
For patients with metastatic breast cancer, the time gained by delaying disease progression must be weighed against the burden of treatment. BioNTech and DualityBio announced on October 26 that the antibody-drug conjugate (ADC) trastuzumab pamirtecan met the primary efficacy endpoint in a Phase 3 trial, but the improvement was limited, and lung toxicity increased compared with previous trials. The companies therefore said the drug may offer patients limited benefit in the current treatment landscape.
The global trial, called DYNASTY-Breast02, enrolled 541 patients with hormone receptor-positive, HER2-low metastatic breast cancer. Their disease had progressed after endocrine therapy, and they had not received chemotherapy for advanced or metastatic disease. Patients were randomized in a one-to-one ratio to receive trastuzumab pamirtecan or physician’s choice of single-agent chemotherapy.
Trastuzumab pamirtecan, also known by its development codes BNT323/DB-1303, is a HER2-targeted ADC carrying a topoisomerase I inhibitor. The trial showed a statistically significant improvement in progression-free survival compared with chemotherapy, but the companies described the magnitude as “limited.” The announcement did not provide median progression-free survival for either group or a hazard ratio, so it is not currently possible to quantify how much additional time patients gained.
OncLive added that the primary endpoint was assessed by an independent central review blinded to patients’ treatment assignments. Progression-free survival measures the time before disease progression or death and cannot be directly equated with longer life. Overall survival, a secondary endpoint, was not yet mature at this interim analysis. Other secondary endpoints covered tumor response, safety, and patient-reported outcomes.
Safety was another key aspect of these results. The companies said the incidence of interstitial lung disease was higher than in previous trials of the drug. Most cases were grade 1 or 2, but a small proportion of patients experienced serious or fatal grade 3–5 events. This comparison was with earlier trials of the same drug; the information released so far is insufficient to determine the difference in pulmonary risk between the drug and chemotherapy groups in this trial.
Of note, according to the enrollment criteria summarized by OncLive, the trial excluded patients with a history of interstitial lung disease, as well as those who had previously received anti-HER2 therapy or an ADC carrying an exatecan-derived topoisomerase I inhibitor. Serious pulmonary events occurred even under these screening criteria, making the incidence, management, and outcomes reported in the subsequent full data important for assessing benefits and risks.
BioNTech and DualityBio said they would discuss the data before deciding on next steps and have not announced the termination of the development program. For this breast cancer trial, meeting the primary endpoint is only the starting point for interpreting the results. Whether the drug can become a meaningful treatment option also depends on the magnitude of improvement, survival and quality-of-life outcomes, and the risks patients bear in return.